Item 9 Labs Corp (INLB)
0.0002
0.00 (0.00%)
USD |
OTCM |
May 01, 16:00
Item 9 Labs Cash from Investing (TTM): -1.459M for June 30, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
June 30, 2023 | -1.459M |
March 31, 2023 | -1.153M |
December 31, 2022 | -3.728M |
September 30, 2022 | -5.160M |
June 30, 2022 | -3.836M |
March 31, 2022 | -5.603M |
December 31, 2021 | -4.166M |
September 30, 2021 | -3.918M |
June 30, 2021 | -3.800M |
March 31, 2021 | -2.297M |
December 31, 2020 | -1.921M |
September 30, 2020 | -0.8869M |
June 30, 2020 | -2.199M |
March 31, 2020 | -6.279M |
December 31, 2019 | -6.494M |
September 30, 2019 | -7.843M |
June 30, 2019 | -6.801M |
March 31, 2019 | -2.811M |
December 31, 2018 | -1.880M |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | 0.00 |
December 31, 2015 | 0.00 |
September 30, 2015 | -0.0067M |
June 30, 2015 | -0.0227M |
March 31, 2015 | -0.0227M |
December 31, 2014 | -0.0227M |
September 30, 2014 | -0.016M |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
December 31, 2013 | 0.00 |
September 30, 2013 | -0.0355M |
June 30, 2013 | -0.0355M |
March 31, 2013 | -0.0755M |
December 31, 2012 | -0.0755M |
June 30, 2012 | 0.0164M |
March 31, 2012 | 0.0164M |
December 31, 2011 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-7.843M
Minimum
Sep 2019
-0.8869M
Maximum
Sep 2020
-3.973M
Average
-3.836M
Median
Jun 2022
Cash from Investing (TTM) Benchmarks
Cantabio Pharmaceuticals Inc | -- |
Q BioMed Inc | -- |
NVN Liquidation Inc | -5.961M |
Affymax Inc | -- |
Scopus BioPharma Inc | 0.00 |